Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131829 · ClinicalTrials.gov registry record · Phase 1
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04131829 is a Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04131829, a Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compulsive disorder.
Conditions Studied
Interventions
- DRUG Fluoxetine - immediate treatment
- DRUG Fluoxetine - delayed treatment
Study Locations (1)
Connecticut
- Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04131829
The ClinicalTrials.gov registry entry for NCT04131829 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,063-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Fluoxetine - immediate treatment is the first listed.
NCT04131829 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04131829 about?
NCT04131829 is a clinical study titled "Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD". The proposed randomized, double-blind research study will use functional magnetic resonance neuroimaging using state-of-the-art HCP acquisition protocols and analytic pipelines, to identify predictors and correlates of response to an accepted first-line pharmacological treatment for obsessive-compul...
What is the current status of trial NCT04131829?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2019-10-14. Estimated completion is 2026-12-31.
What conditions does trial NCT04131829 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT04131829?
The interventions under investigation include: Fluoxetine - immediate treatment (DRUG), Fluoxetine - delayed treatment (DRUG).
Who is sponsoring clinical trial NCT04131829?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131829 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of RR-HNK in OCD
RECRUITING · Phase 1
-
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
RECRUITING · Phase 1
-
Effects of Repeated Psilocybin Dosing in OCD
ACTIVE NOT RECRUITING · Phase 1
-
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 1
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.